Conferences
Conferences
Cecilia BrownConferences | October 5, 2022
The GVHD rate was around 5% in patients receiving Orca-T, a high-precision, regulatory T-cell-engineered donor product.
Read More
Cecilia BrownConferences | October 5, 2022
GVHD occurred more with a fludarabine-based flipped conditioning regimen than with a cyclophosphamide-based flipped regimen.
Cecilia BrownConferences | October 5, 2022
The presence and number of clonal plasma cells in an autograft are predictive of posttransplant outcomes in multiple myeloma.
Cecilia BrownConferences | October 5, 2022
Noncryopreserved and cryopreserved peripheral blood stem cells (PBSC) lead to similar patient outcomes after transplant.
Cecilia BrownConferences | October 5, 2022
Most patients did not have extensive chronic GVHD after a mismatched transplant with this pretransplant conditioning regimen.
Cecilia BrownConferences | October 5, 2022
Patients transplanted with omidubicel had better quality of life than patients transplanted with umbilical cord blood.
Cecilia BrownConferences | October 5, 2022
Patients with CMML who developed GVHD after transplant were less likely to relapse than patients who did not develop GVHD.
Cecilia BrownConferences | October 5, 2022
More than half of patients receiving haploidentical HSCT had GVHD, but age was the only predictive factor for survival.
Cecilia BrownConferences | September 30, 2022
New research suggests that the first complete remission is the best time for allogeneic HSCT in extramedullary AML.
Cecilia BrownConferences | September 30, 2022
Large pericardial effusions leading to acute pericardial tamponade after transplant were not associated with acute GVHD.
Cecilia BrownConferences | September 30, 2022
Use of a female donor for a male undergoing HSCT can raise the risk of GVHD but did not significantly reduce survival.
Cecilia BrownConferences | September 30, 2022
Scores on GVHD risk assessments can predict a patient’s risk of mortality and their likelihood of responding to treatment.
Cecilia BrownConferences | September 30, 2022
The cumulative incidence of GVHD was higher in patients who received a low CD3-positive T-cell dose during transplant.
Cecilia BrownConferences | September 30, 2022
HSCT with antithymocyte globulin and posttransplant cyclophosphamide did not lead to chronic GHVD in most patients.
Cecilia BrownConferences | September 30, 2022
Most patients who received allogeneic HSCT with omidubicel did not develop chronic graft-versus-host disease (GVHD).
Cecilia BrownConferences | September 30, 2022
There are several risk factors for chronic GVHD in patients who received allogeneic haploidentical HSCT.
Cecilia BrownConferences | September 28, 2022
DSA did not lead to graft failure or impact the GVHD incidence in patients who received haploidentical HSCT.
Cecilia BrownConferences | September 28, 2022
Acute graft-versus-host disease may increase the risk of transplant-related mortality by sevenfold in certain patients.
Cecilia BrownConferences | September 28, 2022
Pre-transplant clofarabine and total body irradiation led to a 22% GVHD relapse-free survival rate in patients with leukemia.
Cecilia BrownConferences | September 28, 2022
Extracorporeal photopheresis, a treatment for GVHD, may function by inducing formation of neutrophil extracellular traps.
Advertisement
Advertisement